0 878

Cited 136 times in

Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma

DC Field Value Language
dc.contributor.author한광협-
dc.contributor.author김도영-
dc.contributor.author김만득-
dc.contributor.author김명진-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박미숙-
dc.contributor.author박성일-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author원정윤-
dc.contributor.author이도연-
dc.contributor.author정용은-
dc.contributor.author원종윤-
dc.date.accessioned2016-02-04T11:25:27Z-
dc.date.available2016-02-04T11:25:27Z-
dc.date.issued2015-
dc.identifier.issn0168-8278-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/140392-
dc.description.abstractBACKGROUNDS & AIMS: The aim of this study is to evaluate the prognostic significances of not only the initial and the best response during repeated transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), but if eligible, also the time point of achieving treatment responses. METHODS: Three hundred and fourteen treatment-naïve patients with well-preserved liver function undergoing TACE were recruited. Treatment responses were assessed using modified Response Evaluation Criteria in Solid Tumors. Overall survival (OS) was analyzed using Kaplan-Meier methods, and Cox regression analysis was performed for multivariate analysis. RESULTS: After adjusting other variables, objective response (complete response [CR] and partial response [PR]) as the initial response (adjusted hazard ratio [HR] 0.410) and the best response (adjusted HR 0.335) had independent prognostic significances for OS, respectively (both p < 0.001). Objective responders as the initial response had the longest OS, followed by patients who subsequently achieved objective response after at least two sessions and those who did not achieve objective response during treatment course eventually (52.6, 27.0, and 10.8 months, respectively; log-rank test, p < 0.001). Likewise, patients with CR as the initial response had the longest OS, followed by those who subsequently achieved CR after at least two sessions and those who achieved PR as the best response (70.2, 40.6, and 23.0 months, respectively; log-rank test, p < 0.001). Large (>5 cm) and multiple (⩾ 4) tumors were independently associated with failure to achieve CR after the initial TACE (both p < 0.05). CONCLUSION: Both the initial and the best response predicts OS effectively. However, achievement of treatment response at an early time point is still the most robust predictor for favorable outcomes.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1304~1310-
dc.relation.isPartOfJOURNAL OF HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHCarcinoma, Hepatocellular/mortality-
dc.subject.MESHCarcinoma, Hepatocellular/pathology-
dc.subject.MESHCarcinoma, Hepatocellular/therapy*-
dc.subject.MESHChemoembolization, Therapeutic/methods*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHLiver Neoplasms/mortality-
dc.subject.MESHLiver Neoplasms/pathology-
dc.subject.MESHLiver Neoplasms/therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Invasiveness-
dc.subject.MESHPortal Vein/pathology-
dc.subject.MESHPrognosis-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRemission Induction-
dc.titleComplete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiology (영상의학)-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorKyung Ah Kim-
dc.contributor.googleauthorYong Eun Chung-
dc.contributor.googleauthorMyeong Jin Kim-
dc.contributor.googleauthorMi Suk Park-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorMan Deuk Kim-
dc.contributor.googleauthorSung Il Park-
dc.contributor.googleauthorJong Yoon Won-
dc.contributor.googleauthorDo Yun Lee-
dc.contributor.googleauthorKwang Hyub Han-
dc.identifier.doi10.1016/j.jhep.2015.01.022-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04268-
dc.contributor.localIdA00420-
dc.contributor.localIdA00426-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01463-
dc.contributor.localIdA01510-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA02718-
dc.contributor.localIdA03662-
dc.contributor.localIdA02443-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ01441-
dc.identifier.eissn1600-0641-
dc.identifier.pmid25637785-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0168827815000537-
dc.subject.keywordBest response-
dc.subject.keywordChemoembolization-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordInitial response-
dc.subject.keywordPrognosis-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Man Deuk-
dc.contributor.alternativeNameKim, Myeong Jin-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Mi Sook-
dc.contributor.alternativeNamePark, Sung Il-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameWon, Jong Yun-
dc.contributor.alternativeNameLee, Do Yun-
dc.contributor.alternativeNameChung, Yong Eun-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Man Deuk-
dc.contributor.affiliatedAuthorKim, Myeong Jin-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Mi-Suk-
dc.contributor.affiliatedAuthorPark, Sung Il-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorLee, Do Yun-
dc.contributor.affiliatedAuthorChung, Yong Eun-
dc.contributor.affiliatedAuthorWon, Jong Yun-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.rights.accessRightsnot free-
dc.citation.volume62-
dc.citation.number6-
dc.citation.startPage1304-
dc.citation.endPage1310-
dc.identifier.bibliographicCitationJOURNAL OF HEPATOLOGY, Vol.62(6) : 1304-1310, 2015-
dc.identifier.rimsid51978-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.